We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
VYVANSE (Shire Australia Pty Ltd)
Product name
VYVANSE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
242 working days (255)
Active ingredients
lisdexamfetamine dimesilate
Registration type
EOI
Indication
VYVANSE is now also indicated for the treatment of moderate to severe Binge Eating Disorder (BED) in adults when nonpharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.